World Transplant Games Federation’s Post

👏 To share with you a new algorithm to identify potential ACLF patients, hopefully to help more people. It was recently published in Prof. @Jean Francois D. Cadranel's special issue "Cirrhosis and Its Complications": Johnson A, Habib S. Liver transplantation consideration and evaluation: a life-saving treatment in acute-on-chronic liver failure. Explor Dig Dis. 2024;3:262–74.

In #lung transplantation, a short-term heparin-free anticoagulation strategy using #ECMO is safe and feasible perioperatively. Read More: https://bit.ly/3YgSl3p

Medscape has just featured interim results from the #CHANCE study in a recent article. The CHANCE study aims to compare 1-year graft and patient survival rates post-#livertransplantation in patients with acute-on-chronic liver failure #ACLF grade 2 or 3 versus those with #decompensatedcirrhosis without severe ACLF. The study also evaluates transplant-free survival of patients with ACLF-2 or -3 who are not listed for liver transplantation. Scientific Coordinator of the CHANCE study Rajiv Jalan was interviewed following his presentation at the #EASLCongress 2024. Read the full article on Medscape to learn more about the benefit of liver transplantation in ACLF and how the CHANCE study will impact the future of liver transplantation and patient care. International Liver Transplantation Society ESOT - European Society for Organ Transplantation https://lnkd.in/dwcUMjuV

Coming from the article: 1. DCD Donors in the United States: Donors after circulatory death (DCD) make up more than 30% of the deceased donor pool in the United States. However, organs from these donors tend to have lower transplantation success rates compared to those from brain-dead donors. 2. Cost of Acquiring DCD Livers: The total cost of acquiring a DCD liver for transplantation is $15,029 higher than that of a liver from a brain-dead donor. This cost difference is partly due to 18% of DCD transplantation expenses being attributed to dry runs, where organs cannot be utilized. 3. Impact on Total Costs: DCD transplants account for 34.5% of the total organ acquisition costs, despite representing only 30.3% of the transplantation volume. 4. Strategies to Reduce Costs: To mitigate the costs associated with DCD, strategies such as local organ recovery, transferring donors to nearby hospitals, and conducting more thorough prerecovery organ assessments are recommended. 5. Importance of Expanding DCD: Expanding the use of DCD is crucial for increasing the availability of liver grafts for transplantation. Regarding points 4 and 5, and in my opinion, according to the published evidence, integrating liver perfusion machines into these strategies can significantly enhance the viability of DCD organs, reduce the incidence of dry runs, and improve overall cost-effectiveness; addressing the cost issues, mainly through the use of perfusion technologies, is essential to prevent reversing the progress made in expanding the donor pool and to support the long-term sustainability of DCD transplantation. Great paper!. XVIVO #livertransplantation #livermachineperfusion

📰 We are thrilled to share our latest publication: "New insights in immunomodulation for intestinal transplantation."   📌 Achieving tolerance in solid organ transplantation remains a significant challenge. This is especially true for intestinal grafts due to the small bowel's high immunogenicity. This review highlights the foundational chimerism theory introduced by Thomas Starzl, provides an overview of our current understanding of tolerance in intestinal transplantation, and outlines recent advances in the field. To illustrate, we also focus on the Leuven immunomodulatory protocol, a pro-tolerogenic approach initiated in 2000 which includes several interventions designed to enhance graft acceptance.   👊 Special thanks to Professor Laurens Ceulemans for his tremendous mentorship and unwavering support, and to Professor Jacques Pirenne for his crucial guidance. Gratitude also to all the co-authors for their significant assistance. Emilio Canovai Xin Jin Charlotte Hooft bart vanaudenaerde Caroline Boelhouwer Tim Vanuytsel   🔍 https://lnkd.in/en2CqUwF   #Transplantation #Immunology #IntestinalTransplantation #Immunomodulation #Chimerism #LeuvenProtocol #OrganTransplantation #MedicalResearch #ClinicalAdvances

New therapy proven effective against rejection in kidney transplantation - Medical Xpress New therapy proven effective against rejection in kidney transplantation  Medical Xpress Learn more https://lnkd.in/edCPyCyg

Unveiling Therapeutic Targets for #Liver Damage after Liver Transplantation: Gp78-ACSL4 Axis in Focus https://lnkd.in/eXT4EXVv Liver transplantation is a life-saving procedure, but post-transplant complications remain a challenge. Our latest blog post explores the potential of the Gp78-ACSL4 axis as a therapeutic target to address liver damage after transplantation. This research offers exciting possibilities for improving patient outcomes. In this blog, we delve into the details of the Gp78-ACSL4 axis and its significance for liver health. For more information check the link above. #livertransplant #humanhealth

I am thrilled to announce the publication of my first book chapter on the topic of dd-cfDNA in liver transplantation. This achievement wouldn't have been possible without the guidance of professor Dr. Georgios Tsoulfas and the collaboration with Dr Stella Vasileiadou. This chapter explores the significance of dd-cfDNA as a promising biomarker for evaluating liver graft function and monitoring transplant recipients. Our research highlights how dd-cfDNA levels can serve as a non-invasive tool to detect early signs of graft injury and rejection, providing critical insights for optimizing patient care post-transplantation. You can find our chapter in the link below and learn more about the exciting potential of dd-cfDNA in liver transplantation https://lnkd.in/du5-8qdR #LiverTransplantation #Research #TransplantMedicine #ddcfDNA

Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis Blood (2024) 144 (Supplement 1): 3503 #ASH24

Cohosts Roslyn Mannon, MD and Josh Levitsky, MD are joined by Mackenzie Morris, MD to discuss the key articles of the July issue of the American Journal of Transplantation. https://lnkd.in/dcafHRRs [03:33] Biliary complications after adult-to-adult living-donor liver transplantation: An international multicenter study of 3633 cases https://lnkd.in/dczyw9Zi  [13:07] The impact of time to death in donors after circulatory death on recipient outcome in simultaneous pancreas-kidney transplantation https://lnkd.in/dMM6gsfF  [24:30] Should advanced perfusion be the standard of care for donation after circulatory death liver transplant? https://lnkd.in/dG4_N2G2  [32:20] Immunosuppression Withdrawal in Living-donor Renal Transplant Recipients Following Induction with Anti-thymocyte Globulin and Rituximab: Results of a Prospective Clinical Trial https://lnkd.in/dnyQTAT2  [40:30] Spatial multiomics of arterial regions from cardiac allograft vasculopathy rejected grafts reveal novel insights into the pathogenesis of chronic antibody-mediated rejection https://lnkd.in/dgVKdDrV